semaglutide news october 26 2025 China's Innovent says its GLP-1 works better than Novo's in diabetes study Real-World Weight Loss Among Patients

Using a peptide beyond this window is not advisable, as its potency and sterility can no longer be guaranteed

Program does not include any other medication

Zepbound and Enhanced Weight Loss Zepbound offers a unique approach by targeting both GLP-1 and GIP hormones, fostering enhanced weight loss results

These measures generally move together, and reading across all three gives a fuller picture than any single number

Designed for people with hypermobility and persistent pain, it focuses on how strength and stability are organised and learned by the nervous system, beginning with the feet and progressing through sensory input, coordination, and motor learning

The launch comes as GLP-1 prescriptions have tripled since 2020 and the FDA approved the first oral Wegovy pill in late 2025, signaling continued expansion of these widely-used weight loss and diabetes medications